CAR-T cell therapy research

This study shows hyper-migratory CAR T cells reduce ovarian cancer metastasis and improve survival in mice.

The paper uses in vivo CRISPR screens to identify genes affecting CAR T cell persistence and function in multiple myeloma, finding CDKN1B as a key regulator of late-stage CAR T cell fitness.

This paper uses base editing to introduce dominant-negative mutations in FAS and TGFβR2 in primary T cells, enhancing their anti-tumor efficacy and persistence in solid tumor models.

This paper performs in vivo CRISPR screens in human T cells to identify genetic modifiers of T cell function in solid tumors, finding P2RY8-G13 and GNAS as key regulators.

This study shows that enhancing Fas/FasL signaling improves CAR-T cell bystander killing against antigen-negative tumor cells, reducing antigen escape and improving therapeutic outcomes.

This paper develops dual-antigen targeting CAR-T cells against CD70 and active integrin β2 to overcome AML antigen heterogeneity and reduce off-tumor toxicity.

The paper identifies MPZL1 as a therapeutic target in 1q-amplified solid cancers by repurposing passenger amplifications as Trojan horses for targeted therapy delivery.

The paper identifies unique molecular responses of CAR-T cells in solid tumors through single-cell transcriptomic analysis, revealing immunosuppressive subpopulations and PD-1-independent exhaustion-like features.

This study investigates how Neuropilin-1 (NRP-1) on solid tumors affects CAR T cell function, finding that NRP-1 transfer via trogocytosis may impair CAR T cell activity.

Autofluorescence imaging informs manufacturing conditions that enhance yield and metabolic fitness of CAR T cells for neuroblastoma.

The paper introduces miniCARbids, small human-derived CAR binding domains that show high anti-tumor potency in CAR T cells, outperforming traditional scFvs in some cases.

This study designs a CD33-mesothelin loop CAR to enhance iNK cell efficacy against AML by avoiding fratricide and improving cytotoxicity.

This paper develops CD38KO/CD38-CAR γδT cells for T cell malignancies, showing they effectively target T-ALL without causing fratricide or GvHD.

This study develops a method to generate optimized peptide ligands for CAR-T cell restimulation, demonstrating enhanced expansion and memory development in preclinical models.

The paper develops synthetic cytokine receptors by repurposing natural ectodomains to create orthogonal biosensors for targeted cellular responses.

This paper engineers CCL27 mutants to enhance CAR T-cell efficacy against multiple myeloma by targeting CCR10, achieving results comparable to BCMA CAR-Ts.

SCAN-ACT identifies and prioritizes T cell therapy targets for solid tumors using single-cell transcriptomics and multi-omics data, validating targets through experimental methods.

This study shows that knocking down JNK in CAR-T cells increases their cytotoxicity against ovarian cancer by enhancing granzyme B expression through NFATc1.

This paper develops circRNA-based in vivo panCAR to achieve comprehensive B cell depletion and reconstitution, showing efficacy in treating B cell disorders and aging in mice and non-human primates.

CART-GPT predicts CAR-T therapy efficacy and neurotoxicity risk using a transformer model trained on 1.12 million single-cell RNA-seq profiles with clinical outcomes.

This paper develops a mathematical model to study how healthy B-cells affect CAR-T cell therapy outcomes in B-cell cancers, showing their variable impact based on patient-specific factors.

The paper evaluates how the functional avidity of anti-B7H3 CAR-T constructs relates to their ability to trigger effector function against tumors with varying antigen density.

This paper develops a CAR T-cell targeting the mesothelin stump domain, showing comparable cytotoxicity and effectiveness against resistant tumors compared to standard anti-mesothelin CAR T-cells.

This study develops a binary CAR T cell strategy targeting PSCA and MUC1 with IL-7 expression to improve antitumor potency and persistence in pancreatic tumors.

This study investigates CAR T cell cytotoxic responses, showing they are sensitive to TCR interactions and can be modulated by inhibitory peptides.

This study develops circRNA-based in vivo CAR and vaccines that synergistically enhance anti-tumor immunity in mice.

This study screens TCR-based CAR designs to improve anti-tumor efficacy by incorporating CD28 and CD27 costimulatory domains, showing enhanced performance in mouse tumor models.

This study identifies FASLG expression patterns and shows that FAS-L/FAS auto-regulation governs CAR-T and CAR-NK cell persistence, enhancing antitumor efficacy when FAS is inhibited.

This study uses programmable microparticles to enhance CAR-T cell expansion beyond physiological limits by rewiring signaling pathways.